Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Monday

Praxis Precision Medicines (NASDAQ:PRAX) is projected to issue its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Praxis Precision Medicines to post earnings of ($3.54) per share and revenue of $0.13 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, topping the consensus estimate of ($3.67) by $0.80. On average, analysts expect Praxis Precision Medicines to post ($14.15) EPS for the current fiscal year and ($11.79) EPS for the next fiscal year.

Praxis Precision Medicines Price Performance

Shares of NASDAQ:PRAX opened at $285.93 on Monday. The company has a market capitalization of $7.98 billion, a PE ratio of -22.11 and a beta of 2.85. The business has a fifty day moving average price of $301.28 and a two-hundred day moving average price of $314.42. Praxis Precision Medicines has a 1 year low of $154.45 and a 1 year high of $392.70.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. HC Wainwright reissued a “buy” rating and set a $1,201.00 price objective on shares of Praxis Precision Medicines in a report on Thursday, October 15th. Robert W. Baird set a $514.00 target price on Praxis Precision Medicines in a research note on Friday, August 7th. JPMorgan Chase & Co. assumed coverage on Praxis Precision Medicines in a research report on Friday, October 16th. They set an “overweight” rating and a $700.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $582.00 price target on shares of Praxis Precision Medicines in a research report on Thursday, September 24th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $630.42.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for disorders of the central nervous system. The company applies its Cerebrum™ platform, which combines human genetics, neuroscience and data science, to identify disease mechanisms and advance precision medicines for patients with neurological and psychiatric conditions.

Its pipeline has included investigational treatments for epilepsy and other severe neurological disorders. Key programs have included PRAX-628, a small-molecule antiseizure medicine candidate, and elsunersen, an antisense oligonucleotide program being developed for certain genetically defined forms of epilepsy.